Skip to main content
. 2023 Apr 1;25(5):euad040. doi: 10.1093/europace/euad040

Table 2.

Clinical and programming variables comparing SMART Pass™ on and off

All (n = 348) SP ON (n = 316) SP OFF (n = 32) P
Age 47.0 (35.0–55.0) 53.0 (37.0–59.5) 46.0 (35.0–54.0) 0.079
Male 239 (68.7%) 221 (69.9%) 18 (56.2%) 0.11
Previous atrial fibrillation 12 (3.4%) 10 (3.2%) 2 (6.2%) 0.36
Hypertrophic cardiomyopathy 108 (31.0%) 102 (32.3%) 6 (18.8%) 0.11
Ischaemic heart disease 67 (19.3%) 60 (19.0%) 7 (21.9%) 0.69
Dilated cardiomyopathy 56 (16.1%) 52 (16.5%) 4 (12.5%) 0.56
Arrhythmogenic cardiomyopathy 28 (8.0%) 21 (6.6%) 7 (21.9%) <0.005
Left ventricular ejection fraction <35% 83 (27.5%) 75 (27.6%) 8 (26.7%) 0.92
Secondary prevention 98 (28.2%) 90 (28.5%) 8 (25.0%) 0.68
S-ECG x2 gain 15 (4.3%) 8 (2.5%) 7 (21.9%) ≤ 0.0001
Primary vector 178 (51.1%) 164 (51.9%) 14 (43.8%) 0.38
Secondary vector 128 (36.8%) 117 (37.0%) 11 (34.4%) 0.77
Alternate vector 42 (12.1%) 35 (11.1%) 7 (21.9%) 0.074
QRS (ms) 96 (86–100) 98 (90–104) 95 (85–100) 0.16
Conditional zone (b.p.m.) 200 (200–220) 200 (200–220) 200 (200–220) 0.75
Non-conditional zone (b.p.m.) 70 (61–81) 87 (70–98) 68 (59–81) 0.4
DFT shock impedance (ohms) 250 (230–250) 250 (230–250) 250 (230–250) <0.001
Appropriate therapy 15 (4.3%) 13 (4.1%) 2 (6.2%) 0.57
Inappropriate therapy 27 (7.8%) 16 (5.1%) 11 (34.4%) ≤ 0.0001